Pfizer has signed a $2.6 billion licensing deal with Starna Therapeutics to develop and commercialize in vivo CAR-T programs aimed at autoimmune diseases. The structure includes a $330 million upfront payment, with additional development and commercial milestones potentially reaching $2.3 billion. The partnership gives Pfizer exclusive rights outside Mainland China, Hong Kong, Macau, and Taiwan to advance three pre-investigational in vivo CAR-T programs. Pfizer will lead clinical development and manufacture for early trials at US facilities, while Starna retains control of its RNA delivery and proprietary in vivo CAR-T platform. Strategically, the deal broadens Pfizer’s inflammation and immunology pipeline and leverages its RNA medicine capabilities in parallel with Starna’s CAR-T delivery approach. The agreement also leaves optionality for Pfizer to expand territory and license products in Asia, raising the near-term importance of in vivo engineering differentiation. For the sector, the scale of the transaction is another signal that late-stage capital markets are actively pricing competition around autoimmune cell therapies—especially platforms designed to reduce manufacturing complexity versus ex vivo CAR-T.